Literature DB >> 18777967

Long-term safety of stimulant medications used to treat children with ADHD.

Marc Lerner1, Tim Wigal.   

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a common mental health condition that affects children, adolescents, and adults. Because it is a chronic condition and typically requires effective treatment for several years or more, information on the benefits and risks of long-term pharmacotherapy for ADHD is vital to clinicians. This article reviews the emerging literature on the safety of long-term stimulant medications in ADHD-the most commonly prescribed medications for this condition. Common side effects, including cardiovascular effects, growth effects, and tics, are discussed, as well as treatment of children younger than age 6 and evidence of carcinogenic and reproductive effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18777967     DOI: 10.3928/02793695-20080801-06

Source DB:  PubMed          Journal:  J Psychosoc Nurs Ment Health Serv        ISSN: 0279-3695            Impact factor:   1.098


  4 in total

Review 1.  An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults.

Authors:  Timothy E Wilens; Nicholas R Morrison; Jefferson Prince
Journal:  Expert Rev Neurother       Date:  2011-10       Impact factor: 4.618

2.  Effectiveness of the Challenging Horizons After-School Program for young adolescents with ADHD.

Authors:  Steven W Evans; Brandon K Schultz; Christine E Demars; Heather Davis
Journal:  Behav Ther       Date:  2011-03-30

3.  A randomized controlled trial of cognitive behavioral therapy for ADHD in medication-treated adolescents.

Authors:  Susan E Sprich; Steven A Safren; Daniel Finkelstein; Jocelyn E Remmert; Paul Hammerness
Journal:  J Child Psychol Psychiatry       Date:  2016-03-17       Impact factor: 8.982

4.  Selecting Effective Herbal Medicines for Attention-Deficit/Hyperactivity Disorder via Text Mining of Donguibogam.

Authors:  Hyo Won Bae; Se Yeon Lee; Sung Ji Kim; Hwa Kyoung Shin; Byung Tae Choi; Jin Ung Baek
Journal:  Evid Based Complement Alternat Med       Date:  2019-06-04       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.